It is not a disaster at all.. Just triggers different filing and TAUG has capable attorneys to advise through this landscape.
Furthermore your timeline on VTGN is way off. PHASE 2A is being completely run by the NIH. On there suggestion and FUNDING AV-101 went from being tested for pain to depression. PHASE 2A is expected roughly at the end of Q2 2018 not Q2 2019.
In the interim VTGN has recieved a much stronger US patent with a new clock, the FDA approved an improved formulation of the drug without VTGN having to start over and the FDA gave VTGN fasttrack status.
VTGN is confident regarding Phase 2A and has begun Phase 2 Adjunctive, that trial is expected Q2 2019. An adjunctive trial is great as it usually is a quicker approval process and the fact is old school first line depression drugs fail patients for a variety of reasons over 80% of the time.
Now, AV-101 also has potential indications for Parkinson's and Hodgkinsons and trials could begin on those indications.
Furthermore, now that the opiod crisis has blown up the indication of AV 101 in pain could now be a blockbuster also, especially as it is non addictive and trials hopefully prove no side effects.
The stem cell division could be a surprise as well, that has been pretty quiet of late...
Cheers
News 
Market Data 
Discover 
